Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.

摘要: Since the mid-1980s, permanent prostate brachytherapy has been utilized increasingly as a potentially curative treatment for patients of all ages with clinically localized cancer To determine 8-year biochemical progression-free survival rate who had undergone monotherapeutic organ-confined cancer, we conducted study 202 at Schiffler Cancer Center Wheeling Hospital in Wheeling, W.Va. These without supplemental external beam radiation therapy or androgen deprivation clinical T1b-T2c NxM0 (2002 AJCC) from April 1995 through May 2001. No patient underwent seminal vesicle biopsy pathologic lymph node staging. The median follow-up was 5.2 years. All more than 3 years prior to analysis. Biochemical success defined PSA < 0.4 ng/mL after nadir. Clinical, and dosimetric parameters evaluated included age, T-stage, Gleason score, pretreatment PSA, risk group, percent positive biopsies, isotope, volume, planning V100/150/200, D90, tobacco status, hypertension diabetes. For entire 97.4% Pd-103 93.3% I-125. post-treatment group 0.1 ng/mL. In multivariate analysis, only predicted outcome trend better younger age lesser biopsies. results our indicate that interstitial approach disease high probability Generous periprostatic margins documented quality day 0 postoperative dosimetry are mandatory such outcomes.